Combinatorial Crispr/Cas9 For Suppression Of Latent Hiv-1 Provirus In Vitro

dc.contributor.authorNithya Ravichantar
dc.date.accessioned2022-03-31T07:07:23Z
dc.date.available2022-03-31T07:07:23Z
dc.date.issued2020-11
dc.description.abstractAlthough HAART effectively suppresses HIV-1 replication, its compromised effectiveness against non-B subtypes, the challenge of eliminating latent proviruses, life-long treatment, and viral resistance complicates the cure for HIV-1. CRISPR/Cas9, the latest genome editing tool, can overcome the limitations seen with HAART. By targeting the promoter of HIV-1 (LTR), CRISPR/Cas9 can disrupt the latent reservoirs. Here, we designed an improved CRISPR/Cas9 system, combinatorial CRISPR/Cas9 to concurrently knockdown multiple HIV-1 genes: structural (Pol and Gag), regulatory (Rev and Tat) and accessory genes (Vif). We investigated the efficacy of this tool as a therapy against different viral subtypes in a subset population . Our preliminary data, showed a huge decrease in viral load and we verified the safety of CRISPR/Cas9 in human cell lines.en_US
dc.identifier.urihttp://hdl.handle.net/123456789/15005
dc.publisherUniversiti Sains Malaysiaen_US
dc.subjectCombinatorial Crispr/Cas9en_US
dc.subjectSuppression Of Latent Hiv-1 Provirus In Vitroen_US
dc.titleCombinatorial Crispr/Cas9 For Suppression Of Latent Hiv-1 Provirus In Vitroen_US
dc.typeThesisen_US
Files
License bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: